Form 4: RedHill Biopharma COO Executes Tax-Related Share Sale

Chief Operating Officer Gilead Raday sold 15,740,000 ordinary shares to satisfy tax obligations related to RSU vesting.

Summary

• Gilead Raday, COO of RedHill Biopharma, sold 15,740,000 ordinary shares on April 6, 2026.
• The sale was executed as a 'sell-to-cover' transaction to satisfy tax withholding obligations following the vesting of restricted share units (RSUs).
• The transaction involved 1,574 American Depositary Shares (ADS), where each ADS represents 10,000 ordinary shares.
• The reporting person retains beneficial ownership of 261,060,000 ordinary shares following the transaction.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction is purely administrative and related to tax compliance rather than a strategic divestment.

Positives

• The transaction was non-discretionary and mandated by tax withholding requirements, indicating no change in management's long-term outlook on the company.

Negatives

• The sale represents a reduction in the direct equity stake held by a key executive, though it is purely for tax compliance.

Risks

• Reliance on equity-based compensation for key personnel may lead to periodic sell-to-cover transactions that could be misinterpreted by the market.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Management Comments

• The transaction was effected by the trustee appointed in accordance with the regulations set by the Israeli Tax Authority pursuant to a sell to cover policy and does not represent a discretionary trade by the reporting person.

Industry Context

StockSavvy.ai notes that 'sell-to-cover' transactions are standard industry practice for executives receiving equity-based compensation, serving as a mechanism to manage personal tax liabilities without signaling a lack of confidence in the company's future performance.

Comparison to Industry Standards

• The transaction aligns with standard corporate governance practices for biotech firms where equity compensation is a significant component of executive remuneration.

Stakeholder Impact

• Minimal impact on shareholders as the sale was non-discretionary and limited to tax obligations.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

RedHill Biopharma, RDHL, Insider Trading, Form 4, Biotech, Executive Compensation